Regulations.gov document
Patient-Focused Drug Development for Hereditary Angioedema; Public Meeting; Request for…
Notice · FDA-2017-N-3068 · posted Jul 20, 2017
Key facts
| Document ID | FDA-2017-N-3068-0001 |
|---|---|
| Title | Patient-Focused Drug Development for Hereditary Angioedema; Public Meeting; Request for Comments |
| Document type | Notice |
| Subtype | Request for Comments |
| Agency | FDA |
| Docket | FDA-2017-N-3068 |
| Posted | Jul 20, 2017 |
| Federal Register citation | 82 FR 33503 |
| FR document number | 2017-15202 |
| Comment period opens | Jul 20, 2017 |
| Comments due | Nov 21, 2017 |
| Effective date | Jul 20, 2017 |
At a glance
- 1–9 Pages
- No Open for comment
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: